Skip to content

PR-Web

Press releases worldwide

  • Home
  • Contact
  • Datenschutzerklärung
  • Legal notice

Author: Firma Biognosys

Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine

Posted on 12. October 202123. August 2022 by Firma Biognosys Posted in General Tagged biognosys, biopsy, cancer, clinical, discovery, healthineers, new, pathology, patients, project, research, scout, siemens, umg, with

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider. Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers. The project received […]

Read More

Biognosys Announces New Release of Spectronaut™

Posted on 15. June 202123. August 2022 by Firma Biognosys Posted in General Tagged biognosys, cell, clinical, discovery, lab, learning, machine, mobility, new, protein, ptm, research, spectronaut, thermo, with

Biognosys, a leader in next-generation proteomics solutions for life sciences research and development, announced today the launch of Spectronaut 15. The software provides fast, robust, and seamless data analysis for mass spectrometry (MS) based data-independent acquisition (DIA) proteomics. Thus, Spectronaut enables the […]

Read More

Biognosys Announces Strategic Agreement with Siemens Healthineers

Posted on 13. April 202123. August 2022 by Firma Biognosys Posted in General Tagged assay, biognosys, biomarker, clinical, company, discovery, healthcare, healthineers, lab, medical, power, samples, siemens, testing, with

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it has established a strategic agreement with Siemens Healthineers, a global medical technology company, through its clinical laboratory in Berkeley, California. The agreement leverages Biognosys’ […]

Read More

Biognosys announces Nature Communications publication in collaboration with ETH Zurich, Bayer, and BASF

Posted on 1. September 202023. August 2022 by Firma Biognosys Posted in General Tagged basf, bayer, biognosys, biotech, cancer, cell, chemoproteomic, cropscience, discovery, hupo, learning, machine, new, research, with

Biognosys is pleased to announce the publication of new research findings in Nature Communications on the utility of its LiP technology and workflow for drug target identification. The publication,entitled “A Machine-Learning-Based Chemoproteomic Approach to Identify Drug Targets and Binding Sites in Complex Proteomes”, is […]

Read More

Biognosys Announces Appointment of Dr. Patrick Vink as Chairman

Posted on 17. June 2020 by Firma Biognosys Posted in General Tagged amryt pharma, biognosys, biotechnology, board of directors, drug development, LIFE SCIENCE, novartis, numico, pharmaceutical, Proteomics, research, sanofi-synthelabo, santhera pharmaceuticals, spero therapeutics

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today the appointment of Dr. Patrick Vink as Chairman of the Board of Directors. Dr. Vink replaces Mr. Harry Welten, who joined the Biognosys Board in 2011 and […]

Read More

Posts navigation

Newer posts

Copyright 2016. All rights reserved.


Back To Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more